Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Myeloproliferative neoplasms (MPNs) are rare clonal hematologic malignancies characterized by the excessive production of mature blood cells in the bone marrow due to mutations in hematopoietic stem cells. According to Cancer Therapy Advisor, primary myelofibrosis, one of the major MPN subtypes, has an annual incidence of around 0.3 cases per 100,000 individuals in the United States, with most diagnoses occurring at a median age of 65-67 years. Major therapeutic approaches include JAK inhibitors, interferon therapies, targeted agents, and hematopoietic stem cell transplantation. According to the myeloproliferative neoplasms pipeline analysis by Expert Market Research, increasing research on molecular drivers, expanding clinical trials, and advancements in targeted therapies are expected to strengthen the development of novel treatments and support pipeline growth in the coming years.
-
Major companies involved in the myeloproliferative neoplasms pipeline analysis include AbbVie, Incyte Corporation, and others.
-
Leading drugs currently in the pipeline include IMGN632, INCA035784, JNJ-88549968, and others.
-
The rising clinical focus on JAK inhibitor resistance, expanding trials of novel targeted therapies such as BET and telomerase inhibitors, and increasing combination strategies are strengthening the development of potential disease-modifying treatments.
Report Coverage
The Myeloproliferative Neoplasms Pipeline Analysis Report by Expert Market Research gives comprehensive insights into myeloproliferative neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for myeloproliferative neoplasms. The myeloproliferative neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The myeloproliferative neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with myeloproliferative neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to myeloproliferative neoplasms.
Read more about this report - Request a Free Sample
Myeloproliferative Neoplasms Pipeline Outlook
Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers characterized by the abnormal overproduction of blood cells in the bone marrow. They occur due to mutations in genes regulating hematopoietic stem cells, such as Janus kinase 2, leading to uncontrolled cell proliferation. This process disrupts normal blood formation and may progress to bone marrow fibrosis or leukemia.
Myeloproliferative neoplasms treatment focuses on controlling abnormal blood cell production, relieving symptoms, and preventing complications using Janus kinase inhibitors, cytoreductive drugs, targeted therapies, blood transfusions, and hematopoietic stem cell transplantation. Momelotinib gained regulatory momentum in September 2023 when the United States Food and Drug Administration approved the oral Janus kinase 1 and Janus kinase 2 inhibitor for myelofibrosis patients with anemia. Developed by GlaxoSmithKline, the therapy demonstrated improvements in spleen size, symptom burden, and transfusion independence in Phase III trials.
Myeloproliferative Neoplasms Epidemiology
The pipeline is gaining attention due to measurable disease incidence and ongoing clinical research. According to Cancer Therapy Advisor, the annual incidence of primary myelofibrosis in the United States is about 0.3 cases per 100,000 individuals, with a median patient age of 65–67 years. Additionally, as per Nouf Abutheraa et al., 2023, myeloproliferative neoplasms affect nearly 8 individuals per 100,000 population in the United Kingdom. The growing epidemiological burden and improved diagnosis are supporting the continuous research and development of targeted therapies in the pipeline.
Myeloproliferative Neoplasms – Pipeline Therapeutic Assessment
This section of the report covers the analysis of myeloproliferative neoplasms drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The myeloproliferative neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Recombinant Proteins
- Peptides
- Vaccines
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Myeloproliferative Neoplasms Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 54%, covers a major share of the total myeloproliferative neoplasms clinical trials, highlighting advanced development and strong market potential. Phase I contributes 34%, reflecting robust early-stage innovation, while phase III accounts for 10%, demonstrating promising late-stage candidates. Together, these developments can drive significant growth and treatment options in the market.
Myeloproliferative Neoplasms Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the myeloproliferative neoplasms pipeline analysis include small molecules, monoclonal antibodies, recombinant proteins, peptides, and vaccines. The myeloproliferative neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for myeloproliferative neoplasms. Targeted immune cell therapies are emerging in the myeloproliferative neoplasms drug pipeline to address unmet needs in myelofibrosis. For instance, CK0804, an allogenic Treg cell therapy, modulates the CXCR4/CXCL12 axis and delivers IL-10 to suppress inflammation. It demonstrates disease-modifying effects, reduces pathogenic monocytes, and complements JAK inhibition, offering an off-the-shelf, non-myelosuppressive treatment option for patients.
Myeloproliferative Neoplasms Clinical Trials – Key Players
The EMR report for the myeloproliferative neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed myeloproliferative neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in myeloproliferative neoplasms clinical trials:
- AbbVie
- Incyte Corporation
- Eli Lilly and Company
- Janssen Research & Development, LLC
- BeiGene
- Sumitomo Pharma America, Inc.
- Hangzhou GluBio Pharmaceutical Co., Ltd.
- GlaxoSmithKline
- Bristol-Myers Squibb
- Ajax Therapeutics, Inc.
- Telios Pharma, Inc.
Myeloproliferative Neoplasms – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs myeloproliferative neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of myeloproliferative neoplasms drug candidates.
Drug: IMGN632
Pivekimab Sunirine (IMGN632) is being investigated in an ongoing Phase 1/2 open-label, multi-center clinical study sponsored by AbbVie for patients with untreated or relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and other CD123-positive hematologic malignancies, including myeloproliferative neoplasms. The study is evaluating the maximum tolerated dose, safety, tolerability, pharmacokinetics, immunogenicity, and anti-leukemia activity of the drug. Pivekimab Sunirine is a CD123-targeted antibody-drug conjugate administered intravenously on Day 1 of a 21-day cycle, delivering a cytotoxic payload directly to malignant cells to enhance targeted cell killing. The trial started in January 2018 and is expected to be completed in December 2026.
Drug: INCA035784
INCA035784 is a novel T-cell redirecting antibody being developed by Incyte Corporation for the treatment of myeloproliferative neoplasms. The Phase 1, open-label, multicenter study is evaluating the safety, tolerability, and preliminary clinical activity of the drug in approximately 120 participants. INCA035784 is designed to recognize mutant calreticulin (mutCALR) on malignant cells and simultaneously activate T cells, triggering targeted immune-mediated destruction of mutCALR-positive cancer cells. The therapy is being administered as a systemic antibody treatment and is demonstrating dose-dependent T-cell activation with controlled cytokine release. The study started in October 2025 and is expected to be completed by December 2029.
Drug: JNJ-88549968
JNJ-88549968 is being evaluated in a Phase 1 clinical study sponsored by Janssen Research & Development, LLC, for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms. The objective of this phase is to assess safety, pharmacokinetics, and pharmacodynamics while determining the recommended Phase 2 dose and optimal dosing schedule. JNJ-88549968 is a T-cell-redirecting bispecific antibody designed to selectively target CALR-mutated MPN clones and stimulate T-cell–mediated immune responses against malignant cells. The therapy is being administered as monotherapy for essential thrombocythemia or myelofibrosis and in combination with ruxolitinib or momelotinib in myelofibrosis patients. The study is expected to be completed in December 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Myeloproliferative Neoplasms Pipeline Insight Report
- Which companies/institutions are leading the myeloproliferative neoplasms drug development?
- Which company is leading the myeloproliferative neoplasms pipeline development activities?
- What is the current myeloproliferative neoplasms commercial assessment?
- What are the opportunities and challenges present in the myeloproliferative neoplasms pipeline landscape?
- What is the efficacy and safety profile of myeloproliferative neoplasms pipeline drugs?
- Which company is conducting major trials for myeloproliferative neoplasms drugs?
- Which companies/institutions are involved in myeloproliferative neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in myeloproliferative neoplasms?
Reasons To Buy This Report
The Myeloproliferative Neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for myeloproliferative neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myeloproliferative neoplasms collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Myeloproliferative Neoplasms Epidemiology Forecast
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share